|
|
|
|
| LEADER |
01000caa a2200265 4500 |
| 001 |
OLC1984553631 |
| 003 |
DE-627 |
| 005 |
20230518125356.0 |
| 007 |
tu |
| 008 |
161202s2017 xx ||||| 00| ||eng c |
| 024 |
7 |
|
|a 10.1136/annrheumdis-2016-210566
|2 doi
|
| 028 |
5 |
2 |
|a PQ20170206
|
| 035 |
|
|
|a (DE-627)OLC1984553631
|
| 035 |
|
|
|a (DE-599)GBVOLC1984553631
|
| 035 |
|
|
|a (PRQ)c728-853cce09ac02b3fa94e2888c12f153ec6b16ffb91703436dc24cfc5b3d79f3f40
|
| 035 |
|
|
|a (KEY)0045853820170000076000200003doestheriskoflymphomainpatientswithratreatedwithtn
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
4 |
|a 610
|q DE-600
|
| 084 |
|
|
|a XA 10000
|q AVZ
|2 rvk
|
| 084 |
|
|
|a 44.83
|2 bkl
|
| 100 |
1 |
|
|a Nocturne, Gaetane
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 700 |
1 |
|
|a Seror, Raphaele
|4 oth
|
| 700 |
1 |
|
|a Mariette, Xavier
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|t Annals of the rheumatic diseases
|d London : BMJ Publ. Group, 1939
|g 76(2017), 2, Seite e3-e3
|w (DE-627)129093912
|w (DE-600)7090-7
|w (DE-576)014429772
|x 0003-4967
|7 nnns
|
| 773 |
1 |
8 |
|g volume:76
|g year:2017
|g number:2
|g pages:e3-e3
|
| 856 |
4 |
1 |
|u http://dx.doi.org/10.1136/annrheumdis-2016-210566
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_OLC
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OLC-DE-84
|
| 912 |
|
|
|a GBV_ILN_4012
|
| 912 |
|
|
|a GBV_ILN_4219
|
| 912 |
|
|
|a GBV_ILN_4306
|
| 936 |
r |
v |
|a XA 10000
|
| 936 |
b |
k |
|a 44.83
|q AVZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 76
|j 2017
|e 2
|h e3-e3
|
